Current Gastroenterology Reports

, Volume 5, Issue 1, pp 18–25 | Cite as

Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis

  • Shivakumar Chitturi
  • Jacob George


Nonalcoholic fatty liver disease (NAFLD) has emerged as a ubiquitous liver disorder with occasional serious overtones. Although diabetes and obesity were initially held culpable, insulin resistance (IR) is now considered the fundamental operative mechanism. IR is probably the "first step" in nonalcoholic steatohepatitis (NASH). Oxidative stress may be the elusive "second" of possibly multiple steps in the progression of steatosis to fibrosing steatohepatitis. Because hepatic iron promotes oxidative stress, it was mooted as a contributory cofactor in NASH. This proposal was strengthened by an association with hepatic fibrosis. Subsequent studies have shown neither a significant increase in hepatic iron nor an association between hepatic iron and any of the histologic determinants in NASH. Likewise, the increased prevalence of hemochromatosis gene (HFE) mutations in some studies appears to be largely irrelevant to the development of hepatic fibrosis. Excess hepatic iron may occur in insulin resistance-associated iron overload (IRHIO), characterized by hyperferritinemia with normal to mild increases in transferrin saturation. Although patients with IRHIO have a high prevalence of IR-related metabolic disorders, the relationship of IRHIO to NASH is unclear. A recent study showed improvement in insulin sensitivity with the use of venesection in patients with NAFLD, but this approach cannot be implemented without extensive review.


NASH Hepatic Fibrosis Nonalcoholic Fatty Liver Disease Small Intestinal Bacterial Overgrowth Hepatic Iron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Ludwig J, Viggiano TR, McGill DB, et al.: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:434–438.PubMedGoogle Scholar
  2. 2.
    Brunt EM, Janney CG, Di Bisceglie AM, et al.: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467–2474.PubMedCrossRefGoogle Scholar
  3. 3.
    Caldwell SH, Oelsner DH, Iezzoni JC, et al.: Cryptogenic cirrhosis: clinical characterization and risk factors for underlying liver disease. Hepatology 1999, 29:664–669.PubMedCrossRefGoogle Scholar
  4. 4.
    Reid AE: Nonalcoholic steatohepatitis. Gastroenterology 2001, 121:710–723.PubMedCrossRefGoogle Scholar
  5. 5.
    Teli MR, James OF, Burt AD, et al.: The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714–1719.PubMedCrossRefGoogle Scholar
  6. 6.
    Powell EE, Cooksley WGE, Hansen R, et al.: The natural history of nonalcoholic steatohepatitis: a follow-up study of 42 patients for up to 21 years. Hepatology 1990, 11:74–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Matteoni CA, Younossi ZM, Gramlich T, et al.: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413–1419.PubMedCrossRefGoogle Scholar
  8. 8.
    Ratziu V, Bonyhay L, Di Martino V, et al.: Survival, liver failure and hepatocellular carcinoma in obesity-related cirrhosis. Hepatology 2002, 35:1485–1493.PubMedCrossRefGoogle Scholar
  9. 9.
    Bugianesi E, Leone N, Vanni E, et al.: Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002,123:134–140.CrossRefGoogle Scholar
  10. 10.
    Zen Y, Katayanagi K, Tsuneyama K, et al.: Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2001, 51:127–131.PubMedCrossRefGoogle Scholar
  11. 11.
    Younossi ZM, Diehl AM, Ong JP: Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002, 35:746–752.PubMedCrossRefGoogle Scholar
  12. 12.
    Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 2002, 122:1649–1657.PubMedCrossRefGoogle Scholar
  13. 13.
    Chitturi S, Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001, 21:27–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Tilg H, Diehl AM: Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000, 343:1467–1476.PubMedCrossRefGoogle Scholar
  15. 15.
    Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221–1231.PubMedCrossRefGoogle Scholar
  16. 16.
    Weltman MD, Farrell GC, Hall P, et al.: Hepatocyte cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27:128–133.PubMedCrossRefGoogle Scholar
  17. 17.
    Wigg AJ, Roberts-Thomson IC, Dymock RB, et al.: The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206–211.PubMedCrossRefGoogle Scholar
  18. 18.
    Farrell GC: Is bacterial ash the flash that ignites NASH? Gut 2001, 48:148–149.PubMedCrossRefGoogle Scholar
  19. 19.
    Le Roith D, Zick Y: Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001, 24:588–597.CrossRefGoogle Scholar
  20. 20.
    Svegliati-Baroni G, Ridolfi F, Di Sario A, et al.: Insulin and insulin- like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999, 29:1743–1751.PubMedCrossRefGoogle Scholar
  21. 21.
    Paradis V, Perlemuter G, Bonvoust F, et al.: High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001, 34:738–744.PubMedCrossRefGoogle Scholar
  22. 22.
    Bacon BR, Farakvash MJ, Janney CG, et al.: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107:1103–1109.PubMedGoogle Scholar
  23. 23.
    Marchesini G, Brizi M, Morselli-Labate AM, et al.: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999,107:450–455.CrossRefGoogle Scholar
  24. 24.
    Marchesini G, Brizi M, Bianchi G, et al.: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844–1850. Insulin resistance in patients with NAFLD is as profound as in patients with diabetes.PubMedCrossRefGoogle Scholar
  25. 25.
    Knobler H, Schattner A, Zhornicki T, et al.: Fatty liver: an additional and treatable feature of the insulin resistance syndrome. QJM 1999, 92:73–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Cortez-Pinto H, Camilo ME, Baptista A, et al.: Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999, 18:353–358.PubMedCrossRefGoogle Scholar
  27. 27.
    Tankurt E, Biberoglu S, Ellidokuz E, et al.: Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis [letter]. J Hepatol 1999, 31:963.PubMedCrossRefGoogle Scholar
  28. 28.
    Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al.: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183–1192. Patients with NASH and fatty liver are less sensitive to insulin than are control subjects. The site of insulin resistance is probably peripheral, not hepatic.PubMedCrossRefGoogle Scholar
  29. 29.
    Willner IR, Waters B, Patil SR, et al.: Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001, 96:2957–2961.PubMedCrossRefGoogle Scholar
  30. 30.
    Loguercio C, De Girolamo V, de Sio I, et al.: Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol 2001, 35:568–574.PubMedCrossRefGoogle Scholar
  31. 31.
    Comert B, Mas MR, Erdem H, et al.: Insulin resistance in nonalcoholic steatohepatitis. Dig Liver Dis 2001, 33:353–358.PubMedCrossRefGoogle Scholar
  32. 32.
    Chitturi S, Abeygunasekera S, Farrell GC, et al.: NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373–379. This study found a specific association of NASH (compared with hepatitis C) with insulin resistance and a high prevalence of features of insulin resistance.PubMedCrossRefGoogle Scholar
  33. 33.
    Pagano G, Pacini G, Musso G, et al.: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002 35:367–372.CrossRefGoogle Scholar
  34. 34.
    Rashid M, Roberts EA: Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000, 30:48–53.PubMedCrossRefGoogle Scholar
  35. 35.
    Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12:1106–1110.PubMedCrossRefGoogle Scholar
  36. 36.
    Angulo P, Keach JC, Batts KP, et al.: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30:1356–1362.PubMedCrossRefGoogle Scholar
  37. 37.
    Chitturi S, Weltman M, Farrell GC, et al.: HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002, 36:142–149. The latest in the series of studies examining the association between hepatic iron, HFE, and NASH. The hypothesis that excess hepatic iron is present in NASH and is a determinant of hepatic fibrosis is dispelled in this report.PubMedCrossRefGoogle Scholar
  38. 38.
    Khan MF, Wu X, Tipnis UR, et al.: Protein adducts of malondialdehyde and 4-hydroxynonenal in livers of iron loaded rats: quantitation and localization. Toxicology 2002, 173:193–201.PubMedGoogle Scholar
  39. 39.
    George DK, Goldwurm S, MacDonald GA, et al.: Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998, 114:311–318. The first study that raised the prospect of excess hepatic iron contributing to hepatic fibrosis in NASH.PubMedCrossRefGoogle Scholar
  40. 40.
    Bonkovsky HL, Jawaid Q, Tortorelli K, et al.: Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999, 31:421–429.PubMedCrossRefGoogle Scholar
  41. 41.
    Younossi ZM, Gramlich T, Bacon BR, et al.: Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999, 30:847–850.PubMedCrossRefGoogle Scholar
  42. 42.
    Fargion S, Mattioli M, Fracanzani AL, et al.: Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:2448–2455.PubMedCrossRefGoogle Scholar
  43. 43.
    Moirand R, Mortaji AM, Lor’eal L, et al.: A new syndrome of iron overload with normal transferrin saturation. Lancet 1997, 349:95–97. The first of a series of studies showing an association between hepatic iron overload and insulin resistance. Subsequent studies have expanded this entity and have led to suggestions that venesection may be beneficial in its management.PubMedCrossRefGoogle Scholar
  44. 44.
    Mendler MH, Turlin B, Moirand R, et al.: Insulin resistance-associated hepatic iron overload. Gastroenterology 1999, 117:1155–1163.PubMedCrossRefGoogle Scholar
  45. 45.
    Macdonald GA, Powell LW: More clues to the relationship between hepatic iron and steatosis: an association with insulin resistance? Gastroenterology 1999,117:1241–1244.CrossRefGoogle Scholar
  46. 46.
    Guillygomarch A, Mendler MH, Moirand R, et al.: Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 2001, 35:344–349.CrossRefGoogle Scholar
  47. 47.
    Facchini FS, Hua NW, Stoohs RA: Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002, 122:931–939. This provocative study suggests that iron depletion improves insulin sensitivity in NAFLD.PubMedCrossRefGoogle Scholar
  48. 48.
    Potashnik R, Kozlovsky N, Ben-Ezra S, et al.: Regulation of glucose transport and GLUT-1 expression by iron chelators in muscle cells in culture. Am J Physiol 1995, 269:E1052-E1058.PubMedGoogle Scholar
  49. 49.
    Fernandez-Real JM, Penarroja G, Castro A, et al.: Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002, 51:1000–1004.PubMedCrossRefGoogle Scholar
  50. 50.
    Facchini FS: Effect of phlebotomy on plasma glucose and insulin concentrations. Diabetes Care 1998, 21:2190.PubMedCrossRefGoogle Scholar
  51. 51.
    Hua NW, Stoohs RA, Facchini FS: Low iron status and enhanced insulin sensitivity in lacto-ovo vegetarians. Br J Nutr 2001, 86:515–519. An interesting study suggesting an inverse relationship between insulin sensitivity and body iron stores.PubMedGoogle Scholar

Copyright information

© Current Science Inc. 2003

Authors and Affiliations

  • Shivakumar Chitturi
    • 1
  • Jacob George
    • 1
  1. 1.Storr Liver UnitWestmead Millennium Institute, University of SydneyWestmeadAustralia

Personalised recommendations